CN101208330A - 制备艾美拉唑及其盐的方法 - Google Patents
制备艾美拉唑及其盐的方法 Download PDFInfo
- Publication number
- CN101208330A CN101208330A CNA2006800231940A CN200680023194A CN101208330A CN 101208330 A CN101208330 A CN 101208330A CN A2006800231940 A CNA2006800231940 A CN A2006800231940A CN 200680023194 A CN200680023194 A CN 200680023194A CN 101208330 A CN101208330 A CN 101208330A
- Authority
- CN
- China
- Prior art keywords
- dinaphthol
- inclusion complex
- water
- esomeprazole
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960004770 esomeprazole Drugs 0.000 title claims abstract description 47
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 title claims abstract description 47
- 150000003839 salts Chemical class 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 title claims description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 53
- 239000000203 mixture Substances 0.000 claims abstract description 24
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229960000381 omeprazole Drugs 0.000 claims abstract description 20
- 239000003960 organic solvent Substances 0.000 claims abstract description 17
- 238000001816 cooling Methods 0.000 claims abstract description 5
- 230000003287 optical effect Effects 0.000 claims description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 33
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 13
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 12
- 229940011051 isopropyl acetate Drugs 0.000 claims description 12
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 238000002425 crystallisation Methods 0.000 claims description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 7
- 239000003513 alkali Substances 0.000 claims description 7
- 230000008025 crystallization Effects 0.000 claims description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000002585 base Substances 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims description 4
- 238000000638 solvent extraction Methods 0.000 claims description 3
- UUCCCPNEFXQJEL-UHFFFAOYSA-L strontium dihydroxide Chemical compound [OH-].[OH-].[Sr+2] UUCCCPNEFXQJEL-UHFFFAOYSA-L 0.000 claims description 3
- 229910001866 strontium hydroxide Inorganic materials 0.000 claims description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 2
- 239000000908 ammonium hydroxide Substances 0.000 claims description 2
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical class CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 claims description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims description 2
- PPTXVXKCQZKFBN-UHFFFAOYSA-N (S)-(-)-1,1'-Bi-2-naphthol Chemical compound C1=CC=C2C(C3=C4C=CC=CC4=CC=C3O)=C(O)C=CC2=C1 PPTXVXKCQZKFBN-UHFFFAOYSA-N 0.000 abstract description 4
- 239000011259 mixed solution Substances 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 14
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 239000010410 layer Substances 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- 206010013786 Dry skin Diseases 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- 239000013557 residual solvent Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- MQEUGMWHWPYFDD-JIDHJSLPSA-N magnesium;6-methoxy-2-[(s)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1h-benzimidazole Chemical compound [Mg].C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C MQEUGMWHWPYFDD-JIDHJSLPSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229940043265 methyl isobutyl ketone Drugs 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- KWORUUGOSLYAGD-YPPDDXJESA-N esomeprazole magnesium Chemical compound [Mg+2].C([S@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C.C([S@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C KWORUUGOSLYAGD-YPPDDXJESA-N 0.000 description 1
- 239000006261 foam material Substances 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- WALYXZANOBBHCI-UHFFFAOYSA-K magnesium sodium trichloride hydrate Chemical compound O.[Cl-].[Na+].[Mg+2].[Cl-].[Cl-] WALYXZANOBBHCI-UHFFFAOYSA-K 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- -1 methyl alcohol Chemical compound 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 229940112641 nexium Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 208000000689 peptic esophagitis Diseases 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- FOFFPEFVSRGLOZ-JIDHJSLPSA-N potassium;5-methoxy-2-[(s)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide Chemical compound [K+].C([S@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C FOFFPEFVSRGLOZ-JIDHJSLPSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 159000000008 strontium salts Chemical class 0.000 description 1
- FEVPVZSYBDUVGY-YPPDDXJESA-N strontium;5-methoxy-2-[(s)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide Chemical class [Sr+2].C([S@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C.C([S@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C FEVPVZSYBDUVGY-YPPDDXJESA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
实施例号 | 反应溶剂(v/v) | (S)-(-)-联萘酚(摩尔当量) | 碱(摩尔当量) | 标题化合物的量,g(收率,%) | 光学纯度( %ee) |
34567891011121314 | 乙醇/水(95/5)乙醇/水(70/30)乙醇/水(70/30)乙醇/水(70/30)乙醇/水(70/30)乙醇/水(70/30)乙醇/水(60/40)甲醇/水(70/30)1-丁醇/水(70/30)丙酮/水(60/40)乙腈/水(60/40)1,4-二噁烷/水(50/50) | 0.600.600.500.600.600.600.600.600.600.600.600.60 | NH4OH(0.25)NH4OH(0.25)NH4OH(0.25)NH4OH(0.10)NH4OH(0.50)EtNH2(0.25)NH4OH(0.25)NH4OH(0.25)NH4OH(0.25)NH4OH(0.25)NH4OH(0.25)NH4OH(0.25) | 36.6(80)40.3(88)38.9(85)41.2(90)38.4(84)40.7(89)42.1(92)38.0(83)38.9(85)38.9(86)38.0(81)18.3(40) | 98.898.097.996.297.096.795.698.597.296.395.797.7 |
(S)-(-)-联萘酚的量(摩尔当量) | 光学纯度(%ee) | 颜色 | |
实施例1 | 0.6 | 98.7 | 黄白 |
比较例1 | 0.6 | 20.0 | 黄 |
比较例2 | 1.0 | 82.6 | 黑 |
比较例3 | 1.5 | 92.2 | 黑 |
吸光度 | ||
402nm | 540nm | |
比较例2 | 0.392 | 0.313 |
比较例3 | 0.510 | 0.368 |
实施例1 | 0.010 | 0.001 |
Claims (14)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050068761A KR100641534B1 (ko) | 2005-07-28 | 2005-07-28 | 에스오메프라졸 및 그의 염의 제조방법 |
KR1020050068761 | 2005-07-28 | ||
KR10-2005-0068761 | 2005-07-28 | ||
PCT/KR2006/002719 WO2007013743A1 (en) | 2005-07-28 | 2006-07-11 | Method of preparing esomeprazole and salts thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101208330A true CN101208330A (zh) | 2008-06-25 |
CN101208330B CN101208330B (zh) | 2010-12-22 |
Family
ID=37621395
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006800231940A Expired - Fee Related CN101208330B (zh) | 2005-07-28 | 2006-07-11 | 制备艾美拉唑及其盐的方法 |
Country Status (15)
Country | Link |
---|---|
US (1) | US7888511B2 (zh) |
EP (1) | EP1919897B1 (zh) |
JP (1) | JP4795435B2 (zh) |
KR (1) | KR100641534B1 (zh) |
CN (1) | CN101208330B (zh) |
AU (1) | AU2006273050B2 (zh) |
BR (1) | BRPI0613945A8 (zh) |
CA (1) | CA2616119C (zh) |
HK (1) | HK1118553A1 (zh) |
IL (1) | IL188600A (zh) |
MX (1) | MX2008000431A (zh) |
NZ (1) | NZ566271A (zh) |
RU (1) | RU2382777C2 (zh) |
WO (1) | WO2007013743A1 (zh) |
ZA (1) | ZA200801854B (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102089296A (zh) * | 2008-07-09 | 2011-06-08 | 力奇制药公司 | 高化学纯度埃索美拉唑钠的制备方法和埃索美拉唑的新晶型 |
CN102264724A (zh) * | 2008-12-24 | 2011-11-30 | 新梅斯托克尔卡·托瓦纳·兹德拉维尔公司 | 制备艾美拉唑的方法 |
CN101391993B (zh) * | 2008-10-28 | 2012-07-04 | 安徽美诺华药物化学有限公司 | 通过与(s)-(-)-1,1'-联萘-2,2'-二酚形成包合配合物制备s-奥美拉唑及其盐的方法 |
CN102813651A (zh) * | 2011-06-07 | 2012-12-12 | 成都国为医药科技有限公司 | 一种含埃索美拉唑钠的药物组合物及其制备方法 |
CN102850323A (zh) * | 2011-06-30 | 2013-01-02 | 秦引林 | 一种埃索美拉唑钠的精制方法 |
CN101648943B (zh) * | 2009-09-11 | 2013-05-15 | 南京工业大学 | 一种分离制备包结拆分后主客体中(s)-奥美拉唑的方法 |
CN103145694A (zh) * | 2011-12-06 | 2013-06-12 | 重庆煜澍丰医药有限公司 | 埃索美拉唑钠盐的晶体r及其制备方法和用途 |
CN103420979A (zh) * | 2012-05-17 | 2013-12-04 | 广州莱泰制药有限公司 | 埃索美拉唑钠的精制方法 |
CN107698515A (zh) * | 2017-09-07 | 2018-02-16 | 拉萨泰达医药科技有限公司 | 一种苯并咪唑类络合物的制备方法 |
WO2019223799A1 (zh) * | 2018-05-24 | 2019-11-28 | Liu Li | 埃索美拉唑锶新化合物及其药物组合物和用途 |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2259269B1 (es) | 2005-03-03 | 2007-11-01 | Esteve Quimica, S.A. | Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos. |
CA2631919A1 (en) * | 2005-12-05 | 2007-06-14 | Astrazeneca Ab | New process for the preparation of esomeprazole non-salt form |
ES2325336T3 (es) | 2005-12-28 | 2009-09-01 | Union Quimico-Farmaceutica, S.A. | Procedimiento para la preparacion del enantiomero (s) de omeprazol. |
JP2009542624A (ja) * | 2006-07-05 | 2009-12-03 | ルピン・リミテッド | スルホキシド化合物の光学的に純粋な又は光学的に富化されたエナンチオマーの調製方法 |
WO2008149204A1 (en) * | 2007-06-07 | 2008-12-11 | Aurobindo Pharma Limited | An improved process for preparing an optically active proton pump inhibitor |
US7947840B2 (en) | 2007-09-25 | 2011-05-24 | Hetero Drugs Limited | Process for preparation of enantiomerically pure esomeprazole |
WO2010058409A2 (en) | 2008-11-18 | 2010-05-27 | Hetero Research Foundation | Optical purification of esomeprazole |
WO2010097583A1 (en) | 2009-02-24 | 2010-09-02 | Cipla Limited | Esomeprazole potassium polymorph and its preparation |
WO2010118575A1 (en) * | 2009-04-16 | 2010-10-21 | Chengdu Organic Chemicals Co., Ltd, Chinese Academy Of Science | Racemic enantiomers resoluting |
WO2010148314A2 (en) * | 2009-06-19 | 2010-12-23 | Dr. Reddy's Laboratories Ltd. | Preparation of esomeprazole and its pharmaceutically acceptable salts |
EP2486032A4 (en) * | 2009-10-09 | 2013-03-27 | Hetero Research Foundation | RACEMATSPALTUNG SUBSTITUTED 2- (2-PYRIDINYLMETHYLSULFINYL) -1H-BENZIMIDAZOLE |
US8748619B2 (en) | 2009-11-12 | 2014-06-10 | Hetero Research Foundation | Process for the resolution of omeprazole |
KR20120114356A (ko) * | 2010-02-12 | 2012-10-16 | 에스티브 퀴미카 에스.에이. | 에스오메프라졸 나트륨염의 제조공정 |
CN102321072B (zh) * | 2011-08-08 | 2013-07-03 | 天津市汉康医药生物技术有限公司 | 埃索美拉唑钠半水化合物 |
EP2980086B1 (en) | 2014-07-29 | 2016-06-15 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Efficient process for the preparation of esomeprazole (S)-binol complex |
CN104447737A (zh) * | 2014-11-05 | 2015-03-25 | 沈阳化工大学 | 一种泰妥拉唑的手性拆分分离方法 |
US20220306593A1 (en) * | 2019-08-29 | 2022-09-29 | Tokyo University Of Science Foundation | Method for preparing enantiomer of sulfoxide compound, and system for preparing enantiomer |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9002043D0 (sv) | 1990-06-07 | 1990-06-07 | Astra Ab | Improved method for synthesis |
SE9301830D0 (sv) * | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
SE510650C2 (sv) | 1997-05-30 | 1999-06-14 | Astra Ab | Ny förening |
CN1087739C (zh) * | 1998-12-28 | 2002-07-17 | 中国科学院成都有机化学研究所 | 光学纯的苯并咪唑类抗消化性溃疡药物的包结拆分制备法 |
DE19951960C2 (de) | 1999-10-28 | 2002-06-27 | Gruenenthal Gmbh | Verfahren zur Herstellung als Ulkustherapeutika geeigneter Benzimidazol-Derivate |
EP1515963B1 (en) * | 2002-06-27 | 2007-02-14 | Dr. Reddy's Laboratories Ltd. | A process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof |
ES2259269B1 (es) | 2005-03-03 | 2007-11-01 | Esteve Quimica, S.A. | Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos. |
-
2005
- 2005-07-28 KR KR1020050068761A patent/KR100641534B1/ko active IP Right Grant
-
2006
- 2006-07-11 EP EP06757770.0A patent/EP1919897B1/en not_active Not-in-force
- 2006-07-11 ZA ZA200801854A patent/ZA200801854B/xx unknown
- 2006-07-11 MX MX2008000431A patent/MX2008000431A/es active IP Right Grant
- 2006-07-11 US US11/996,657 patent/US7888511B2/en active Active
- 2006-07-11 JP JP2008523792A patent/JP4795435B2/ja not_active Expired - Fee Related
- 2006-07-11 CN CN2006800231940A patent/CN101208330B/zh not_active Expired - Fee Related
- 2006-07-11 BR BRPI0613945A patent/BRPI0613945A8/pt not_active IP Right Cessation
- 2006-07-11 WO PCT/KR2006/002719 patent/WO2007013743A1/en active Application Filing
- 2006-07-11 CA CA2616119A patent/CA2616119C/en not_active Expired - Fee Related
- 2006-07-11 RU RU2008107599/04A patent/RU2382777C2/ru not_active IP Right Cessation
- 2006-07-11 NZ NZ566271A patent/NZ566271A/en not_active IP Right Cessation
- 2006-07-11 AU AU2006273050A patent/AU2006273050B2/en not_active Ceased
-
2008
- 2008-01-06 IL IL188600A patent/IL188600A/en not_active IP Right Cessation
- 2008-11-13 HK HK08112468.0A patent/HK1118553A1/xx not_active IP Right Cessation
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102089296A (zh) * | 2008-07-09 | 2011-06-08 | 力奇制药公司 | 高化学纯度埃索美拉唑钠的制备方法和埃索美拉唑的新晶型 |
CN101391993B (zh) * | 2008-10-28 | 2012-07-04 | 安徽美诺华药物化学有限公司 | 通过与(s)-(-)-1,1'-联萘-2,2'-二酚形成包合配合物制备s-奥美拉唑及其盐的方法 |
CN102264724A (zh) * | 2008-12-24 | 2011-11-30 | 新梅斯托克尔卡·托瓦纳·兹德拉维尔公司 | 制备艾美拉唑的方法 |
CN101648943B (zh) * | 2009-09-11 | 2013-05-15 | 南京工业大学 | 一种分离制备包结拆分后主客体中(s)-奥美拉唑的方法 |
CN102813651A (zh) * | 2011-06-07 | 2012-12-12 | 成都国为医药科技有限公司 | 一种含埃索美拉唑钠的药物组合物及其制备方法 |
CN102850323A (zh) * | 2011-06-30 | 2013-01-02 | 秦引林 | 一种埃索美拉唑钠的精制方法 |
CN103145694A (zh) * | 2011-12-06 | 2013-06-12 | 重庆煜澍丰医药有限公司 | 埃索美拉唑钠盐的晶体r及其制备方法和用途 |
CN103145694B (zh) * | 2011-12-06 | 2016-01-20 | 重庆煜澍丰医药有限公司 | 埃索美拉唑钠盐的晶体r及其制备方法和用途 |
CN103420979A (zh) * | 2012-05-17 | 2013-12-04 | 广州莱泰制药有限公司 | 埃索美拉唑钠的精制方法 |
CN103420979B (zh) * | 2012-05-17 | 2016-04-20 | 广州莱泰制药有限公司 | 埃索美拉唑钠的精制方法 |
CN107698515A (zh) * | 2017-09-07 | 2018-02-16 | 拉萨泰达医药科技有限公司 | 一种苯并咪唑类络合物的制备方法 |
WO2019223799A1 (zh) * | 2018-05-24 | 2019-11-28 | Liu Li | 埃索美拉唑锶新化合物及其药物组合物和用途 |
CN110526899A (zh) * | 2018-05-24 | 2019-12-03 | 刘力 | 埃索美拉唑锶新化合物及其药物组合物和用途 |
Also Published As
Publication number | Publication date |
---|---|
IL188600A0 (en) | 2008-04-13 |
US7888511B2 (en) | 2011-02-15 |
WO2007013743A1 (en) | 2007-02-01 |
HK1118553A1 (en) | 2009-02-13 |
RU2382777C2 (ru) | 2010-02-27 |
KR100641534B1 (ko) | 2006-11-01 |
CN101208330B (zh) | 2010-12-22 |
JP2009502906A (ja) | 2009-01-29 |
AU2006273050B2 (en) | 2009-08-27 |
CA2616119C (en) | 2010-05-18 |
RU2008107599A (ru) | 2009-09-10 |
MX2008000431A (es) | 2008-03-10 |
JP4795435B2 (ja) | 2011-10-19 |
CA2616119A1 (en) | 2007-02-01 |
AU2006273050A1 (en) | 2007-02-01 |
US20080194828A1 (en) | 2008-08-14 |
ZA200801854B (en) | 2009-08-26 |
NZ566271A (en) | 2010-01-29 |
EP1919897A4 (en) | 2009-12-09 |
EP1919897A1 (en) | 2008-05-14 |
EP1919897B1 (en) | 2014-07-02 |
BRPI0613945A8 (pt) | 2016-06-07 |
IL188600A (en) | 2011-12-29 |
BRPI0613945A2 (pt) | 2011-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101208330B (zh) | 制备艾美拉唑及其盐的方法 | |
ES2320172T3 (es) | Procedimiento para la produccion de 5-(4-(4-(5-ciano-3-indolil)-butil)-1-piperazinil)-benzofuran-2-carboxamida. | |
KR100879409B1 (ko) | (s)-베포타스틴의 제조방법 및 이에 사용되는 중간체 | |
CN106380409A (zh) | 一种左旋沙丁胺醇及其盐的制备方法 | |
RU2387656C2 (ru) | Способ получения гидробромида галантамина | |
US10875835B2 (en) | Method for producing 2-acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione | |
TWI491607B (zh) | 4,4’-(1-甲基-1,2-乙二基)-雙-(2,6-哌二酮)之新製法 | |
CN106543076A (zh) | 制备阿伐斯汀的方法 | |
CN112654603B (zh) | 乐伐替尼的制备方法 | |
CA2560353A1 (en) | Process for manufacture of racemic carvedilol | |
WO2011010579A1 (ja) | 光学活性ニペコタミドの製造方法 | |
US20050192433A1 (en) | Metallic salt of N4-acylcytidine derivatives, and a method for producing N4-acylcytidine derivatives using the same | |
JP4093608B2 (ja) | 光学活性2−フェノキシプロピオン酸の製造方法 | |
JP5503930B2 (ja) | 3−アミノ−1−tert−ブトキシカルボニルピペリジンの精製方法およびそのクエン酸塩 | |
JPS58172365A (ja) | S−(カルボキシメチル)−(r)−システイン及びs−(カルボキシメチル)−(s)−システインの収得法 | |
WO2016142165A1 (en) | Improved process for the optical purification of esomeprazole | |
CN117088939A (zh) | 一种匹多莫德的制备方法 | |
KR100397491B1 (ko) | 광학활성 (s)-벤즈옥사진 유도체 및 그의 제조방법 | |
JP2001064275A (ja) | イソクマリン誘導体の光学分割方法 | |
JPH023628A (ja) | 光学活性1−メチル−3−フェニルプロピルアミンの製法 | |
JPH023627A (ja) | 光学活性1−メチル−3−フェニルプロピルアミンの製造法 | |
KR20080093308A (ko) | 라세믹 오메프라졸로부터 에스오메프라졸의 개선된제조방법 | |
KR19980076017A (ko) | 무정형 세팔로스포린에스테르 유도체의 제조방법 | |
KR20060125218A (ko) | 광학활성 벤족사진 유도체의 제조방법 | |
JPH0253755A (ja) | 光学活性1−メチル−3−フェニルプロピルアミンの製法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1118553 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1118553 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: HANMI PHARMACEUTICAL INDUSTRIAL CO., LTD. Free format text: FORMER OWNER: HANMI PHARM. CO., LTD. Effective date: 20110310 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: GYEONGGI, SOUTH KOREA TO: SEOUL, SOUTH KOREA |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110310 Address after: Seoul, South Kerean Patentee after: Hanmi Pharm Ind Co.,Ltd. Address before: Gyeonggi Do, South Korea Patentee before: Hanmi Pharm. Co., Ltd. |
|
C56 | Change in the name or address of the patentee |
Owner name: HANMI SCIENCE CO., LTD. Free format text: FORMER NAME: HANMI HOLDINGS CO., LTD. |
|
CP03 | Change of name, title or address |
Address after: Gyeonggi Do, South Korea Patentee after: Hanmi Holdings Co., Ltd. Address before: Seoul, South Kerean Patentee before: Hanmi Pharm Ind Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101222 Termination date: 20170711 |
|
CF01 | Termination of patent right due to non-payment of annual fee |